Live feed17:18:16·274dPRReleasevia QuantisnowKura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical OncologyByQuantisnow·Wall Street's wire, on your screen.KURA· Kura Oncology Inc.Health Care